Latest news from Sparsentine

sparsentanis a new small molecule drug candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). FSGSis a pattern of damage to the glomeruli (filtration units) of the kidneys, which has a variety of causes that lead to decreased kidney function and progression to kidney failure. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the orphan drug spaxentan for marketing on FSGS.

A dual study is the largest interventional study of FSGS to date. This is a global, randomized, multi-center, double-blind, parallel-controlled Phase 3 clinical trial evaluating sparsentane in 371 patients. Efficacy and safety in patients with primary FSGS aged 8 to 75 years old. After a two-week washout period, patients were randomized to receive either parsentan or irbesartan (active comparator) in a 1:1 ratio, with subsequent dose titration to the maximum tolerated dose of 800 mg parsentan or 300 mg irbesartan. In February 2021, the company announced that the key Sparsentan test conducted at FSGS< The phase 3 dual study met its prespecified interim FSGS partial response (FPRE) endpoint with statistical significance. FPRE is a clinically meaningful endpoint defined as the ratio of urine protein to creatinine (UP/C) ≤1.5g/g, and UP/C decreased by 40% compared with the baseline. After 36 weeks of treatment, 42.0%received sparsenstattreated patients achieved FPRE, compared with 26.0% of patients treated with irbesartan (p = 0.0094). The study's primary efficacy endpoint in the United States is the overall slope of eGFR from Day 1 to Week 108 of treatment. The primary efficacy endpoint in Europe is the chronic slope of eGFR from week 6 to week 108 of treatment after the initial acute effect of randomized treatment. In 2023May , the company announced topline primary efficacy results from FSGS sparsentan dual studies. The dual study did not meet the primary efficacy eGFR slope endpoint at 108 weeks of treatment. Sparsentine's secondary and top-line exploratory endpoints trended favorably. Treatment with sparsentan resulted in a reduction in proteinuria that was sustained for 108 weeks of treatment. Results of the two-year analysis show that sparsentan was well tolerated and had a safety profile comparable to irbesartan. Patients who completed the double-blind portion of the treatment study were eligible to participate in an open-label extension of the trial. 2023In December the company announced that it was conducting span>FSGSThe data are undergoing additional analysis and plans are planned to re-engage with the FDA later in2024 after the company considers additional evidence. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.